[1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- manufacturers
- PPARγ agonist 3
-
- $1980.00
-
2026-07-27
- CAS:2011801-48-0
- Purity:
- Supply Ability: 10g
|
| | [1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- Basic information |
| | [1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- Chemical Properties |
| Boiling point | 622.2±55.0 °C(Predicted) | | density | 1.17±0.1 g/cm3(Predicted) | | pka | 15.84±0.50(Predicted) |
| | [1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- Usage And Synthesis |
| Uses | PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib[1]. | | References | [1] Schoepf AM, et al. Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators. Eur J Med Chem. 2020 Jan 1;185:111748. DOI:10.1016/j.ejmech.2019.111748 |
| | [1,1'-Biphenyl]-2-carboxamide, 4'-[(2-propyl-1H-benzimidazol-1-yl)methyl]- Preparation Products And Raw materials |
|